Kairos Pharma (KAPA) Stock Price, News & Analysis

Company Overview

Kairos Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted radiopharmaceutical therapies for oncology. Established in 2016 and headquartered in New York, the company aims to harness the precision of radiolabeled compounds to selectively deliver therapeutic radiation to tumor cells while minimizing off-target effects. By pairing novel radionuclides with proprietary targeting agents, Kairos Pharma seeks to expand the scope of radioisotope therapy beyond traditional applications and address key unmet medical needs in cancer treatment.

The company’s lead asset, KAI-101, is a targeted alpha therapy currently in Phase 1 clinical trials for metastatic prostate cancer. KAI-101 couples a high-energy alpha-emitting isotope to a prostate-specific membrane antigen (PSMA)–binding ligand, enabling focused delivery of radiation to malignant tissue. In parallel, Kairos Pharma is advancing KAI-102, a beta-emitting compound designed for advanced breast cancer, and is exploring additional indications across solid tumors. Preclinical studies have demonstrated favorable biodistribution profiles and promising anti-tumor activity for both candidates.

Kairos Pharma conducts its research and manufacturing operations in the United States, with strategic partnerships in Europe to support clinical site networks and regulatory filings. The company collaborates with leading academic centers—such as MD Anderson Cancer Center and the University of Zurich—to leverage expertise in nuclear medicine and oncology. These collaborations facilitate translational research activities, patient enrollment for clinical trials, and the refinement of imaging-based biomarkers to monitor treatment response.

Leadership at Kairos Pharma is anchored by Chief Executive Officer Dr. Karen Lin, who brings over 20 years of experience in radiopharmaceutical development, and Chief Medical Officer Dr. Samuel Ortiz, a recognized expert in nuclear oncology. Supported by a multidisciplinary management team and a board comprising industry veterans and scientific advisors, the company is positioned to advance its pipeline with the goal of delivering new therapeutic options to patients with limited treatment choices.

Key Stats

• Today's Range: $1.02 to $1.82
• 50-Day Range: $0.45 to $1.17
• 52-Week Range: $0.40 to $4.00
• Volume: 241.73 million shs
• Average Volume: 616,918 shs
• Market Capitalization: $19.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.33
• Consensus Rating: Buy

Kairos Pharma Stock Analysis - MarketRank™

Kairos Pharma scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Kairos Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kairos Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Kairos Pharma has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for KAPA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kairos Pharma does not currently pay a dividend.

Dividend Growth

Kairos Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for KAPA.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.66

News Sentiment

Kairos Pharma has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Kairos Pharma this week, compared to 1 article on an average week.

Search Interest

11 people have searched for KAPA on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Kairos Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kairos Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.30% of the stock of Kairos Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

KAPA Stock Analysis - Frequently Asked Questions

How have KAPA shares performed this year?

Kairos Pharma's stock was trading at $1.53 at the start of the year. Since then, KAPA shares have decreased by 23.5% and is now trading at $1.17.

How do I buy shares of Kairos Pharma?

Shares of KAPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:KAPA
• CIK: 1962011
• Web: N/A
• Phone: (818) 404-5541
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kairos Pharma: $8.33
• High Price Target: $12.00
• Low Price Target: $4.00
• Potential Upside/Downside: +612.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.52
• Quick Ratio: 7.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 3.34

Miscellaneous

• Outstanding Shares: 16,850,000
• Free Float: 11,238,000
• Market Cap: $19.71 million
• Optionable: N/A
• Beta: N/A